Takeda Pharmaceutical Ltd ADR (TAK) Stock Price, Quote & News

Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombi...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 81 3 3278-2111

Fax: 81 3 3278-2000

Website: www.takeda.com

Address:

1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, Japan

Quantumup Mar. 11 at 8:06 PM

Raymond James (a/o 3/9) reiterated $EPRX at a Strong Buy rating and an $18 PT. $REGN - SNY $APGE BMY $TAK AZN - AMGN $PHAT Raymond James said in its note: Following our recent initiation of coverage and investor discussions thereafter, we are circling back to recap our thesis on EPRX, which we believe has among the best 2026 risk/reward setups in our coverage universe into Phase 2b RESOLVE data for EP-104GI in EoE expected in 2H26. Reiterate Strong Buy. Here's what else Raymond James had to say:

0 · Reply

Maestro_Ioannis Mar. 5 at 3:18 PM

$TAK long term position here, offers some gains lately, with some good recent news. If you are in such low beta stocks, check also potential go-private BARK. With the stock around 0.80 it has received 2 buy-out proposals in cash at 0.90 & 1.10.

0 · Reply

briefingcom Mar. 2 at 1:30 PM

$TAK: Takeda Pharma reports FDA accepts rusfertide NDA, grants priority review for polycythemia vera https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260302051822TAK&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

0 · Reply

StockNews_Live Mar. 2 at 7:00 AM

$TAK Takeda and Protagonist Therapeutics announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted Priority Review for rusfertide. Rusfertide is an inve…

0 · Reply

Quantumup Feb. 24 at 9:24 PM

Stifel🏁 $ALMS and said, We are initiating coverage with a Buy Rating and $44 Target Price on Alumis Inc. (ALMS). $TAK $BMY $JNJ - $PTGX NVS ABBV Stifel added, Our positive thesis on the stock is predicated on our view that next-generation TYK2s with the ability to achieve full target coverage have the potential to grow into an important oral class with the benefit of no Boxed Warning. To that end, topline data in Psoriasis from ALMS' Envudeucitinib provides support for the target coverage thesis with data that looks superior to both Zasocitinib and Sotyktu—more details likely to come at AAD (3/27-3/31). Ultimately, success here derisks broader development not only in SLE (data 3Q26) but also in the plethora of other diseases where there's clear support for the TYK2 target/coverage hypothesis. Looking ahead, with an NDA filing on track in psoriasis in 2H26, we see a path towards a strategic transaction to support the launch and expansion of the TYK2+ pipeline.

0 · Reply

Quantumup Feb. 24 at 2:12 PM

Wolfe Research🏁 $CNTA Outperform/$40, and said, The Next Big Idea in CNS - A High-Conviction Orexin Play; Initiate with OP; $40 PT $ALKS $TAK $HRMY $ESALY Wolfe Research added, While multiple orexin-2 agonists demonstrated strong clinical data in late-stage studies, we believe CNTA's ORX750 would become the best-in-class product and generate >$3B US peak sales ➢ Key upcoming catalysts: Additional Ph2 data for higher doses expected in 1Q26, we expect good data which should move the stock up significantly (+40-50%).

0 · Reply

Quantumup Feb. 24 at 12:48 PM

Bloom Burton🏁 $EPRX Buy/$14 $REGN - $SNY $TAK BMY AZN PFE $PHAT Here's what Bloom Burton said in its initiation report: https://x.com/Quantumup1/status/2026277237402538359?s=20

0 · Reply

jlz1 Feb. 20 at 4:51 PM

$TAK wen $23

0 · Reply

Quantumup Feb. 20 at 12:41 PM

Raymond James resumed coverage on $EPRX and said, We are resuming coverage of Eupraxia Pharmaceuticals (EPRX) with a Strong Buy rating and $18 target price. $SNY - REGN $TAK $BMY AZN PFE $PHAT Raymond James added, The company's DiffuSphere platform enables the encapsulation of virtually any small molecule, creating drug-infused nanoparticles with greatly extended dosing intervals (~12 months) and localized tissue deposition. Their lead asset is EP-104GI, a DiffuSphere formulation of fluticasone being developed for the treatment of eosinophilic esophagitis (EoE). We see EP-104GI possessing best-in-class potential as a steroid treatment in PPI-refractory EoE patients, with topline data from Part B of the ongoing placebo-controlled Phase 2 RESOLVE study expected in 2H26.

0 · Reply

EingeLTrade Feb. 13 at 3:17 PM

💊 Takeda Pharmaceutical 🛑 Non-stop stock 🫸/🫷 $TAK

0 · Reply

Market Cap	56.55B
Revenue (ttm)	30.24B
Net Income (ttm)	712.32M
EPS (ttm)	N/A
PE Ratio	11.11
Forward PE	10.97
Profit Margin	2.36%
Debt to Equity Ratio	0.63

Volume	2,500,300
Avg Vol	2,955,778
Day's Range	N/A - N/A
Shares Out	3.18B
Stochastic %K	31%
Beta	0.01
Analysts	Strong Sell
Price Target	$20.13